Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Medical Officer | August 24, 2023 | February 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date August 24, 2023 · Filed February 06, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,110 |
Reported balance
After 2023-08-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-08-24 · Grant · Acquired 50,000 · Balance 120,110 F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.
F2: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,601 | $2.46 | $8,858.46 |
DisclosureSEC source: 0001415889-24-022426 · form4-08282024_040807.xml · nonDerivative · entry 2 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,261 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 9,888 | $2.66 | $26,302.08 |
DisclosureSEC source: 0001415889-24-022426 · form4-08282024_040807.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,862 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| July 23, 2024 Filed Jul 23, 2024 22:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 86 | $6.98 | $600.28 |
DisclosureSEC source: 0001415889-24-019972 · form4-07232024_100729.xml · nonDerivative · entry 2 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,750 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 22:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 18,421 | $7.06 | $130,052.26 |
DisclosureSEC source: 0001415889-24-019972 · form4-07232024_100729.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,836 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-24-008542 · form4-03192024_040351.xml · derivative · entry 2 Goldenberg Gary · CIK 0001741938 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-03-15 F2 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008542 · form4-03192024_040351.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,257 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:35 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 3,036 | $2.97 | $9,016.92 |
DisclosureSEC source: 0001209191-23-055534 · doc4.xml · nonDerivative · entry 2 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,257 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:35 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 5,817 | $2.93 | $17,043.81 |
DisclosureSEC source: 0001209191-23-055534 · doc4.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,293 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 20:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-047519 · doc4.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,110 F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered. Read SEC document |
| August 24, 2023 Filed Feb 6, 2025 21:15 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003234 · form4a-02062025_040211.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,110 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale. F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:23 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | SaleCommon Stock | 28,699 | $4.83 | $138,616.17 |
DisclosureSEC source: 0001209191-23-043304 · doc4.xml · nonDerivative · entry 2 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,110 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:23 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043304 · doc4.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,809 F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:26 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-23-015497 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 20:12 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 23,809 | $2.10 | $49,998.90 |
DisclosureSEC source: 0001209191-22-040600 · doc4.xml · nonDerivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,809 Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:36 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013199 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:03 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0001209191-21-016984 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| August 01, 2020 Filed Aug 3, 2020 22:35 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001209191-20-044549 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-08-01 F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on August 1, 2021 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 21:03 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantOption Grant (right to buy) · Derivative | 5,834 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001209191-20-036345 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 11, 2020 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:54 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-19-037168 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 12, 2019 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:30 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 17,502 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038320 · doc4.xml · derivative · entry 1 Goldenberg Gary · CIK 0001741938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2028-06-14 F1 · derivative.exercise_date: 1/3 of the total shares subject to the option shall vest on June 14, 2019 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.